Understanding viral infections in infants with bronchiolitis after Nirsevimab use

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to monitor the viral epidemiology of acute bronchiolitis in infants under 12 months after the implementation of Nirsevimab, a long-acting antibody against RSV. It will include infants presenting with their first episode of bronchiolitis at the pediatric emergency department over three epidemic seasons. Clinical data will be collected alongside nasopharyngeal swabs, which will undergo multiplex Polymerase Chain Reaction to identify the responsible respiratory viruses. The study seeks to understand how Nirsevimab affects the prevalence of various respiratory viruses in this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Infant aged 12 months or less
* Admitted to the pediatric emergencies services during one of the three epidemic years: 2024-2025, 2025-2026 and 2026-2027
* With clinical diagnosis of first episode of acute bronchiolitis by the emergency pediatrician
* With nasopharyngeal swab for virological diagnosis

Exclusion Criteria:

* Refusal of one or more of the infants parents to participate in the study
* Infants parents refused to be called back for follow-up
* No nasopharyngeal swab taken

Where it's running

• Rouen University Hospital
  Rouen, France Recruiting

Study contacts

• Study coordinator: Hortense PETAT, Doctor
• Email: secretariat.DRC@chu-rouen.fr
• Phone: 0232888265

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Montelukast for acute bronchiolitis in infants and young children

  This study tests whether adding montelukast to standard care helps shorten hospital stays and relieve symptoms in indoor patients aged 4 weeks to 2 years with acute bronchiolitis.

  Recruiting Phase 2 Pakistan Institute of Medical Sciences · Islamabad, Federal · NCT07770464

• Shortening antibiotic courses for common throat and chest infections in primary care with doctor–pharmacist teamwork and viral‑circulation updates

  This project will test whether giving primary care doctors and pharmacists extra information about circulating viruses plus a shared protocol helps shorten antibiotic courses for patients with common respiratory infections.

  Recruiting University Hospital, Caen · Caen · NCT07359287

• Preventing RSV in Babies: Nirsevimab with or without maternal RSV vaccine

  This study tests whether giving a monoclonal antibody to newborns, with or without the mother’s vaccination during pregnancy, can better protect infants from RSV than giving just one option.

  Recruiting Phase 3 Centre Hospitalier Annecy Genevois · La Roche-sur-Yon · NCT07232706

• Evaluating Nirsevimab's effect on RSV hospitalizations in infants

  This study is testing if a new antibody called Nirsevimab can help prevent infants under one year old from being hospitalized due to RSV infections.

  Recruiting at 8 sites Meyer Children's Hospital IRCCS · Arezzo, Arezzo and 7 other locations · NCT06856967

• Comparing two methods for stopping high flow nasal cannula treatment in infants with acute bronchiolitis

  This study is testing whether stopping high flow nasal cannula treatment right away or gradually is better for helping infants with acute bronchiolitis leave the hospital sooner and safely.

  Recruiting at 4 sites Kuopio University Hospital · Joensuu and 3 other locations · NCT06321133

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.